Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Capital Leases: 2011-2024

Historic Capital Leases for Niagen Bioscience (NAGE) over the last 9 years, with Sep 2024 value amounting to $2,000.

  • Niagen Bioscience's Capital Leases fell 85.71% to $2,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $2,000, marking a year-over-year decrease of 85.71%. This contributed to the annual value of $12,000 for FY2023, which is 45.45% down from last year.
  • Latest data reveals that Niagen Bioscience reported Capital Leases of $2,000 as of Q3 2024, which was down 66.67% from $6,000 recorded in Q2 2024.
  • Niagen Bioscience's Capital Leases' 5-year high stood at $36,000 during Q1 2020, with a 5-year trough of $2,000 in Q3 2024.
  • Over the past 3 years, Niagen Bioscience's median Capital Leases value was $13,000 (recorded in 2023), while the average stood at $12,750.
  • Per our database at Business Quant, Niagen Bioscience's Capital Leases grew by 11.11% in 2020 and then crashed by 85.71% in 2024.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Capital Leases stood at $20,000 in 2020, then crashed by 51.85% to $11,000 in 2021, then reached $22,000 in 2022, then slumped by 45.45% to $12,000 in 2023, then crashed by 85.71% to $2,000 in 2024.
  • Its last three reported values are $2,000 in Q3 2024, $6,000 for Q2 2024, and $9,000 during Q1 2024.